{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:06:12Z","timestamp":1785391572439,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejpb.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T15:34:04Z","timestamp":1674056044000},"page":"25-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Solid-state properties of Nifurtimox. Preparation, analytical characterization, and stability of an amorphous phase"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-478X","authenticated-orcid":false,"given":"Aldana B.","family":"Moroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Perez","family":"Mayoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-8540","authenticated-orcid":false,"given":"Diego F.","family":"Lionello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7124-2507","authenticated-orcid":false,"given":"Daniel R.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-2178","authenticated-orcid":false,"given":"Teodoro S.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1099-3686","authenticated-orcid":false,"given":"Natalia.L.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.01.008_b0005","unstructured":"H. Herlinger, K.-H. Mayer, S. Petersen, M. Bock, Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten. Patent DE 1170957, 1964 to Bayer A.G."},{"key":"10.1016\/j.ejpb.2023.01.008_b0010","unstructured":"H. Herlinger, K.-H. Mayer, S. Petersen, M. Bock, Novel 5-nitro-furfurylidene-(2)-derivatives and process for producing the same. Patent US 3262930, 1966 to Bayer A.G."},{"key":"10.1016\/j.ejpb.2023.01.008_b0015","unstructured":"World Health Organization. (2021). World Health Organization model list of essential medicines: 22nd list (2021). World Health Organization. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/345533 (accessed 23.12.22)."},{"key":"10.1016\/j.ejpb.2023.01.008_b0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.pt.2006.09.011","article-title":"The future of Chagas disease control","volume":"22","author":"Schofield","year":"2006","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejpb.2023.01.008_b0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1358\/dot.2021.57.4.3251712","article-title":"Update on nifurtimox for treatment of Chagas disease","volume":"57","author":"Thakare","year":"2021","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejpb.2023.01.008_b0030","unstructured":"WHO. Chagas Disease (American Trypanosomiasis); WHO: Geneva, Switzerland, 2017. http:\/\/www.who.int\/neglected_diseases\/diseases\/en\/ (accessed 28.9.22)."},{"key":"10.1016\/j.ejpb.2023.01.008_b0035","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/nature09221","article-title":"Chagas disease: a new worldwide challenge","volume":"465","author":"Coura","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.01.008_b0040","unstructured":"G.L. Saulnier Sholler, N. Swamy, S. Kalkunte, R.K. Singh, L. Brard, K.K. Kim, Nitrofuran compounds for the treatment of cancer and angiogenesis. Patent US 9220714, 2015."},{"key":"10.1016\/j.ejpb.2023.01.008_b0045","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.drudis.2019.06.017","article-title":"Toward a repositioning of the antibacterial drug nifuroxazide for cancer treatment","volume":"24","author":"Bailly","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2023.01.008_b0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2003","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0055","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1128\/AAC.05139-14","article-title":"Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties","volume":"59","author":"Moraes","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.01.008_b0060","unstructured":"H. Kramer, K. Bauer, K. Schlossmann, W. Vater, Process for the production of solid preparations of sparingly soluble medicinally active compounds in a very finely divided form. Patent GB 1456618A, 1975."},{"key":"10.1016\/j.ejpb.2023.01.008_b0065","unstructured":"The International Pharmacopeia 10th Ed., Nifurtimox (Nifurtimoxum) monograph, WHO: Geneva, Switzerland, 2020. https:\/\/digicollections.net\/phint\/2020\/index.html#d\/ b.6.1.252 (accessed 29.09.22)."},{"key":"10.1016\/j.ejpb.2023.01.008_b0070","article-title":"Stable tablet formulation of nifurtimox and process for producing the same","volume":"3750527A1","author":"Bayer","year":"2020","journal-title":"Patent EP"},{"key":"10.1016\/j.ejpb.2023.01.008_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105940","article-title":"Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets \u2013 implications for quality control and application","volume":"166","author":"Stass","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0080","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/bcp.13650","article-title":"Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system","volume":"84","author":"Moral Sanchez","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.01.008_b0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/bscb.19880971131","article-title":"Molecular structure in the solid state (X-ray diffraction) and in solution (lH and 13C NMR) of nifurtimox and two pyrazol-1-yl analogs","volume":"97","author":"Foces-Foces","year":"1988","journal-title":"Bull. Soc. Chim. Belg."},{"key":"10.1016\/j.ejpb.2023.01.008_b0090","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ardp.19923251205","article-title":"Determination of the stereochemistry of chemotherapeutics derived from 5-nitrofurfural: NOE difference spectroscopy as a simple and reliable method","volume":"25","author":"Holzer","year":"1992","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejpb.2023.01.008_b0095","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2471\/BLT.17.205807","article-title":"Monographs for medicines on WHO\u2019s Model List of Essential Medicines","volume":"96","author":"Roth","year":"2018","journal-title":"Bull. World. Health. Org."},{"key":"10.1016\/j.ejpb.2023.01.008_b0100","article-title":"Physical stability and dissolution behaviors of amorphous pharmaceutical solids: Role of surface and interface effects","volume":"25","author":"Shi","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(01)00098-9","article-title":"Amorphous pharmaceutical solids: Preparation, characterization and stabilization","volume":"48","author":"Yu","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.01.008_b0110","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1517\/17425247.2014.911728","article-title":"Refining stability and dissolution rate of amorphous drug formulations","volume":"11","author":"Grohganz","year":"2014","journal-title":"Expert Opin. Drug. Deliv."},{"key":"10.1016\/j.ejpb.2023.01.008_b0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cmdc.201800612","article-title":"State of the art of pharmaceutical solid forms: from crystal property issues to nanocrystals formulation","volume":"14","author":"Couillaud","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejpb.2023.01.008_b0120","unstructured":"https:\/\/www.drugs.com\/newdrugs\/fda-approves-lampit-nifurtimox-chagas-children-5317. html. (accessed 29.08.22)."},{"issue":"1344","key":"10.1016\/j.ejpb.2023.01.008_b0125","first-page":"e1","article-title":"Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail","volume":"24","author":"Crespillo-And\u00fajar","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejpb.2023.01.008_b0130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1039\/C7TX00061H","article-title":"A comparison of toxicity and toxicokinetics in rats and dogs following twenty-eight-day, repeat-dose oral administration of nifurtimox","volume":"6","author":"Li","year":"2017","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.ejpb.2023.01.008_b0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.2042-7158.1998.tb03301.x","article-title":"Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates","volume":"50","author":"Gonzalez-Martin","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.01.008_b0140","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1021\/cg200492w","article-title":"Solubility advantage of amorphous drugs and pharmaceutical cocrystals","volume":"11","author":"Babu","year":"2011","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2023.01.008_b0145","doi-asserted-by":"crossref","unstructured":"S. Khodadadi, G.M.H. Meesters, Amorphous APIs: improved release, preparation, characterization, in: H. Merkus, G. Meesters, W. Oostra (Eds.), Particles and Nanoparticles in Pharmaceutical Products. AAPS Advances in the Pharmaceutical Sciences Series, vol. 29, Springer, Cham, Switzerland, 2018, pp. 329\u2013346.","DOI":"10.1007\/978-3-319-94174-5_9"},{"key":"10.1016\/j.ejpb.2023.01.008_b0150","first-page":"322","article-title":"Changing the salt, changing the drug","volume":"266","author":"Davies","year":"2009","journal-title":"Pharm. J."},{"key":"10.1016\/j.ejpb.2023.01.008_b0155","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1021\/jm1002638","article-title":"Strategies at the interface of drug discovery and development: Early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates","volume":"53","author":"Palucki","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2023.01.008_b0160","unstructured":"Amorphous Drugs: Benefits and Challenges. M. Rams-Baron, R. Jachowicz, E. Boldyreva, D. Zhou, W. Jamroz, M. Paluch (Eds.), Springer, New York, USA, 2018."},{"key":"10.1016\/j.ejpb.2023.01.008_b0165","article-title":"A comprehensive approach toward concomitant triclabendazole polymorphism in pharmaceutical products","volume":"62","author":"Salazar-Rojas","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2023.01.008_b0170","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpba.2018.06.019","article-title":"Chemometrics-assisted study of the interconversion between the crystalline forms of nimodipine","volume":"158","author":"Calvo","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2023.01.008_b0175","doi-asserted-by":"crossref","first-page":"e11317","DOI":"10.1016\/j.heliyon.2022.e11317","article-title":"A study of the heat-mediated phase transformations of praziquantel hydrates. evaluation of their impact on the dissolution rate","volume":"8","author":"Salazar-Rojas","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ejpb.2023.01.008_b0180","series-title":"Solid State Characterization of Pharmaceuticals","year":"2011"},{"key":"10.1016\/j.ejpb.2023.01.008_b0185","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s11095-010-0129-3","article-title":"Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin","volume":"27","author":"Trasi","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.01.008_b0190","series-title":"Infrared and Raman Spectroscopy: Principles and Spectral Interpretation 2nd Edici\u00f3n","year":"2017"},{"key":"10.1016\/j.ejpb.2023.01.008_b0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/05704928.2015.1044663","article-title":"Near-Infrared spectroscopy: Effective tool for screening of polymorphs in pharmaceuticals","volume":"50","author":"Chadha","year":"2015","journal-title":"Appl. Spectrosc. Rev."},{"key":"10.1016\/j.ejpb.2023.01.008_b0200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s10973-009-0560-z","article-title":"Thermal behaviour and spectroscopic studies of complexes of some divalent transitional metals with 2-benzoyl-pyridilizonicotinoylhydrazone","volume":"101","author":"Ababei","year":"2010","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2023.01.008_b0205","doi-asserted-by":"crossref","unstructured":"I. Zarafu, M. Badea, G. Ionit\u00b8a, M.C. Chifiriuc, C. Bleotu, M. Popa, P. Ionit\u00b8a, A. Tatibouet, R, Olar. Thermal, spectral and biological characterisation of copper(II) complexes with isoniazid-based hydrazones, J. Therm. Anal. Calorim. DOI: 10.1007\/s10973-018-7853-z.","DOI":"10.1007\/s10973-018-7853-z"},{"key":"10.1016\/j.ejpb.2023.01.008_b0210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/05704929108050883","article-title":"Near-infrared spectroscopy of synthetic polymers","volume":"26","author":"Miller","year":"1991","journal-title":"Appl. Spectrosc. Rev."},{"issue":"12","key":"10.1016\/j.ejpb.2023.01.008_b0215","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.xphs.2018.08.010","article-title":"Applications of powder X-ray diffraction in small molecule pharmaceuticals: achievements and apsiprations","volume":"107","author":"Naveen","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0220","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1039\/C8NJ05946B","article-title":"Spectroscopic (FT-IR, FT-Raman, 13C SS-NMR) and quantum chemical investigations to explore the structural insights of nitrofurantoin-4-hydroxybenzoic acid cocrystal","volume":"43","author":"Shukla","year":"2019","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejpb.2023.01.008_b0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpba.2018.11.001","article-title":"Solid-state NMR analysis of crystalline and amorphous indomethacin: an experimental protocol for full resonance assignments","volume":"165","author":"Lu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2023.01.008_b0230","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1021\/acs.molpharmaceut.2c00479","article-title":"New development in understanding drug\u2013polymer interactions in pharmaceutical amorphous solid dispersions from solid-state nuclear magnetic resonance","volume":"19","author":"Pugliese","year":"2022","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.ejpb.2023.01.008_b0235","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1021\/acs.chemmater.8b04643","article-title":"Molecular insights into carbon dioxide sorption in hydrazone-based covalent organic frameworks with tertiary amine moieties","volume":"31","author":"Gottschling","year":"2019","journal-title":"Chem. Mater."},{"key":"10.1016\/j.ejpb.2023.01.008_b0240","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1021\/cg401866x","article-title":"Substituent and solvent effects on intermolecular interactions in crystals of N -acylhydrazone derivatives: Single-crystal X-ray, solid-state NMR, and computational studies","volume":"14","author":"Mazur","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2023.01.008_b0245","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1021\/acs.jpclett.1c01750","article-title":"15N Solid-state NMR as bright eyes to see the isomerization of the azo bond: revision of tris(\u03b2-hydroxyl-azo)-benzene to tris(\u03b2-ketohydrazo)-cyclohexane in porous organic polymers","volume":"12","author":"Luo","year":"2021","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.ejpb.2023.01.008_b0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dyepig.2017.10.023","article-title":"15N NMR study of (E)- and (Z)-2-(2-(2-hydroxy-4-nitrophenyl)hydrazono)-1- phenylbutane-1,3-diones. A suitable method for analysis of hydrazone isomers","volume":"150","author":"Ly\u010dka","year":"2018","journal-title":"Dyes Pigm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2020.116152","article-title":"Solid-state NMR spectroscopy in pharmaceutical sciences","volume":"135","author":"Li","year":"2021","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.ejpb.2023.01.008_b0260","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1021\/cg400518w","article-title":"Approach of cocrystallization to improve the solubility and photostability of tranilast","volume":"13","author":"Geng","year":"2013","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2023.01.008_b0265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1358\/mf.1998.20.3.485666","article-title":"Micronization: a method of improving the bioavailability of poorly soluble drugs","volume":"20","author":"Chaumeil","year":"1998","journal-title":"Meth. Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.01.008_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrysgro.2022.126601","article-title":"Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers","volume":"585","author":"Yunxia","year":"2022","journal-title":"J. Cryst. Growth"},{"key":"10.1016\/j.ejpb.2023.01.008_b0275","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ejpb.2013.09.002","article-title":"Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats","volume":"85","author":"Nielsen","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0280","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jps.20302","article-title":"Trends in solubility of polymorphs","volume":"94","author":"Pudipeddi","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0285","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1080\/03639045.2019.1665062","article-title":"A review of methods for solubility determination in biopharmaceutical drug characterisation","volume":"45","author":"Veseli","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0290","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2010.06.032","article-title":"Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process","volume":"396","author":"Park","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0295","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jpba.2007.07.002","article-title":"Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: Solid-state characterisation of a trihydrate form","volume":"45","author":"Bartolomei","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2023.01.008_b0300","first-page":"181","article-title":"Investigation of physicochemical properties and in-vitro in-vivo evaluation of agomelatine polymorphs","volume":"8","author":"Du","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0305","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/10837450.2013.871033","article-title":"Preparation and characterization of polymorphs of the glucocorticoid deflazacort","volume":"20","author":"Kassuha","year":"2015","journal-title":"Pharm. Dev. Tech."},{"key":"10.1016\/j.ejpb.2023.01.008_b0310","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0378-5173(02)00196-5","article-title":"Stabilization of amorphous indomethacin by co-grinding in a ternary mixture","volume":"241","author":"Watanabe","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0315","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jps.23346","article-title":"Polymorphic transformation of anhydrous caffeine upon grinding and hydrostatic pressurizing analyzed by low-frequency Raman spectroscopy","volume":"102","author":"H\u00e9doux","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0378-5173(95)00033-F","article-title":"The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs","volume":"122","author":"Mosharraf","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0325","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/acs.molpharmaceut.7b00152","article-title":"Atorvastatin as a promising crystallization inhibitor of amorphous probucol: Dielectric studies at ambient and elevated pressure","volume":"14","author":"Knapik-Kowalczuk","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.008_b0330","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/pharmaceutics13030389","article-title":"Co-amorphous drug formulations in numbers: recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies","volume":"13","author":"Liu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.01.008_b0335","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.xphs.2021.05.010","article-title":"Microwave-induced in situ drug amorphization using a mixture of polyethylene glycol and polyvinylpyrrolidone","volume":"110","author":"Hempel","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0340","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/jps.21983","article-title":"Process-induced phase transformation of berberine chloride hydrates","volume":"99","author":"Tong","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.008_b0345","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.chemolab.2006.07.006","article-title":"Application of SIMPLISMA purity function for variable selection in multivariate regression analysis: A case study of protein secondary structure determination from infrared spectra","volume":"88","author":"Bogomolov","year":"2007","journal-title":"Chemometr. Intell. Lab. Syst."},{"key":"10.1016\/j.ejpb.2023.01.008_b0350","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpba.2013.12.036","article-title":"A dynamic thermal ATR-FTIR\/chemometric approach to the analysis of polymorphic interconversions. Cimetidine as a model drug","volume":"92","author":"Calvo","year":"2014","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:49:48Z","timestamp":1760546988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":70,"alternative-id":["S0939641123000085"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.008","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solid-state properties of Nifurtimox. Preparation, analytical characterization, and stability of an amorphous phase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}